Who are Once daily immunosuppression regimen's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/once-daily-immunosuppression-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Once daily immunosuppression regimen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Once daily immunosuppression regimen (Once daily immunosuppression regimen) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive regimen. Area: Immunology.

marketed Immunosuppressive regimen Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Once daily immunosuppression regimen (Once daily immunosuppression regimen) — Washington University School of Medicine. A once-daily immunosuppressive regimen that reduces the frequency of drug administration while maintaining therapeutic immunosuppression, likely through combination or sustained-release formulation of established immunosuppressive agents.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Once daily immunosuppression regimen TARGET	Once daily immunosuppression regimen	Washington University School of Medicine	marketed	Immunosuppressive regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive regimen class)

Washington University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Once daily immunosuppression regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/once-daily-immunosuppression-regimen. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab